نتایج جستجو برای: refractory nhl lymphoma
تعداد نتایج: 155852 فیلتر نتایج به سال:
Radioimmunotherapy is a new cancer therapy that combines the cytotoxicity of radiation with the tumor-specific targeting of monoclonal antibodies. Yttrium 90 (Y-90) ibritumomab tiuxetan (Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), includ...
Non-Hodgkin lymphoma (NHL) is the eighth most common malignancy worldwide. Diffuse large B cell lymphoma (DLBCL) is the most frequent subtype, accounting for >30% of NHL cases. Advances in novel approaches in the last two decades, such as immunotherapy with rituximab, have achieved improvements in terms of overall and long-term survival rates. The current standard of care for the firstline trea...
We retrospectively compared outcomes of patients with relapsed/refractory non-Hodgkin lymphoma (NHL) who underwent stem cell transplantation (SCT) with stable disease or better following a novel combination of lenalidomide and rituximab (LR) treatment and did not undergo SCT in a phase I/II clinical trial. We retrospectively compared outcomes of patients who underwent SCT with that of patients ...
Treatment for childhood and adolescent non-Hodgkin lymphoma (NHL) has been optimised within the major biological subgroups for the last 30 years. Event-free survival rates reach almost 90% for mature B-cell NHL (B-NHL), 80% for lymphoblastic lymphomas (LBL) and 70% for anaplastic large cell lymphomas (ALCL). The efficacy of the front-line treatment leaves highly refractory relapsed disease, and...
Non-Hodgkin lymphoma (NHL) and leukemia are among the most common cancers worldwide. While the treatment of NHL/leukemia of B-cell origin has much progressed with the introduction of targeted therapies, few treatment standards have been established for T-NHL/leukemia. As presentation in both B- and T-NHL/leukemia patients is often aggressive and as prognosis for relapsed disease is especially d...
Introduction: Mature B-cell non-Hodgkin's lymphoma (MB-NHL) and T-cell lymphoblastic (T-LBL) account for ∼50% ∼20%, respectively, among the different pediatric NHL entities. Our understanding of genetic lesions profiling these patients may help to improve clinical management with lymphomas. The aim this study is analyze mutational status associations between features treatment outcomes in Chine...
Extranodal natural killer cell (NK) T lymphoma (ENKL) is a rare type of non Hodgkins lymphoma, accounting for 5% 10% total NHL cases.
Non-Hodgkin lymphoma (NHL) comprises of heterogeneous group lymphoid malignancies originating from lympho-reticular tissues and is quite uncommon in pregnancy (0.8 cases per 1,00,000 women). Anaplastic large cell (ALCL) a large-cell neoplasm with anaplastic morphology classified under NHL. Here, 31 year old primigravida diagnosed NHL ALCL subtype third trimester, started on chemotherapy which r...
Background: The clinical presentation of non-Hodgkin lymphoma (NHL) varies tremendously depending upon the type of lymphoma and the areas of involvement. NHL can rarely present as an abdominal mass compressing the inferior vena cava. The clinical presentation due to obstruction of inferior vena cava has often been called the inferior vena cava syndrome (IVCS). It can present acutely or chronica...
BACKGROUND Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore underto...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید